Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Clinical Journal of the American Society of Nephrology : CJASN|December 17, 2009
Relationship among length of facility ownership, clinical performance, and mortalityDavid Van Wyck, John Robertson, Allen Nissenson, et al.Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis|September 14, 2002
Comparison of vancomycin versus cefazolin as initial therapy for peritonitis in peritoneal dialysis patientsQuresh Khairullah, Robert Provenzano, Jukaku Tayeb, et al.Current Medical Research and Opinion|October 7, 2006
Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfaPatrick Lefebvre, Francis Vekeman, Brenda Sarokhan, et al.Clinical Journal of the American Society of Nephrology : CJASN|January 30, 2009
Ferumoxytol as an intravenous iron replacement therapy in hemodialysis patientsRobert Provenzano, Brigitte Schiller, Madhumathi Rao, et al.Journal of Clinical Pharmacology|July 1, 2020
Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis PatientsRobert Provenzano, James Tumlin, Raja Zabaneh, et al.Clinical Journal of the American Society of Nephrology : CJASN|February 22, 2008
C.E.R.A. corrects anemia in patients with chronic kidney disease not on dialysis: results of a randomized clinical trialIain C Macdougall, Rowan Walker, Robert Provenzano, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|August 5, 2015
Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patientsAnatole Besarab, Robert Provenzano, Joachim Hertel, et al.Clinical Journal of the American Society of Nephrology : CJASN|August 7, 2021
Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical TrialsRobert Provenzano, Lynda Szczech, Robert Leong, et al.American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 6, 2016
Roxadustat (FG-4592) Versus Epoetin Alfa for Anemia in Patients Receiving Maintenance Hemodialysis: A Phase 2, Randomized, 6- to 19-Week, Open-Label, Active-Comparator, Dose-Ranging, Safety and Exploratory Efficacy StudyRobert Provenzano, Anatole Besarab, Steven Wright, et al.Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|February 25, 2021
Roxadustat for anemia in patients with end-stage renal disease incident to dialysisRobert Provenzano, Evgeny Shutov, Liubov Eremeeva, et al.Pageof 3